Jennifer K. Trittmann, MD, MPH, is Assistant Professor in the Division of Neonatology, Department of Pediatrics at The Ohio State University College of Medicine and Principal Investigator in the Center for Perinatal Research at The Research Institute at Nationwide Children’s Hospital. Dr. Trittmann’s research focuses on bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension (PH), a life-threatening neonatal disease characterized by progressive pulmonary vascular endothelial dysfunction and smooth muscle cell proliferation. Currently, there are no available predictive biomarkers or curative therapies for BPD-PH. Our labs at The Research Institute have discovered three potential biomarkers for BPD-PH: arginase-1 (ARG1), asymmetric dimethylarginine (ADMA), N?N?-dimethylaminohydrolase-1 (DDAH1), that are differentially expressed in neonatal patients with BPD-PH versus BPD alone. Therefore, Dr. Trittmann aims to further develop ARG1, ADMA, and DDAH1 as clinical biomarkers for BPD-PH and to discover their mechanism of action as it relates to BPD-PH pathogenesis, in order to precisely target treatment to improve outcomes for neonatal patients with BPD-PH.